P2.01-040 CXC Chemokine Receptor 3 and ELR Motif Negative CXC Chemokine Ligand Axis in Non-Small Cell Lung Cancer

Abstract

Conclusion: Differences in the metabolomics profiles were apparent and demonstrated the preliminary feasibility of distinguishing early stage NSCLC cases from controls and adenocarcinomas from squamous cell carcinomas using metabolomics techniques. Validation of this methodology on a larger, prospectively accrued, cohort is planned in order to optimize model fit and to assess the diagnostic and NSCLC subtype discriminatory performance in the clinical setting.